Investor Toolbox
Read Transcript
Transcript not yet available.
JNJ Coverage
Event
Johnson & Johnson (JNJ) Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania
Feb 18, 2026
Event
Johnson & Johnson (JNJ) RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer
Feb 18, 2026
Event
Johnson & Johnson (JNJ) FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month
Feb 17, 2026
Transcript
Johnson & Johnson (JNJ) Q4 2025 Earnings Call Transcript
Jan 26, 2026
Transcript
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
Jan 22, 2026
Transcript
Johnson & Johnson (JNJ) Q3 2025 Earnings Call Transcript
Jan 22, 2026
News
Infographic: How Johnson & Johnson (JNJ) performed in Q4 2025
Jan 21, 2026
Research
Johnson & Johnson: Healthcare Outlook
Jan 20, 2026